Glenmede Trust’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Glenmede Trust’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-12,150	Closed	-$2K	–	3016
2017 Q2	$2K	Hold	12,150	–	–	﹤0.01%	2551
2017 Q1	$2K	Buy	+12,150	New	+$2K	﹤0.01%	2551

Other funds holding NWBO

LDB

Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return

WPP

Whalerock Point Partners Providence, Rhode Island $587M AUM 29.61% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

Glenmede Trust's NWBO Position: Q3 2017 in Review

Glenmede Trust sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2017, closing a stake of 12,150 shares — an estimated $2K sold.

Glenmede Trust first reported a position in NWBO in Q1 2017 and held it in 2 quarters. The position peaked at $2K in Q2 2017. 4 funds tracked by Wall St. Rank hold NWBO as of Q3 2017.

Glenmede Trust reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2017 after selling out during the quarter.
Glenmede Trust sold 12,150 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2017, an estimated $2K.
Glenmede Trust first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2017 and held it in 2 quarters.
Glenmede Trust's Northwest Biotherapeutics, Inc. Common stock position peaked at $2K in Q2 2017.
4 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2017.

Based on Glenmede Trust's 13F filing for Q3 2017, filed 14 Nov 2017.